Drugmakers Escape Cancer Drug Antitrust Claims For Now

By Jared Foretek · June 6, 2024, 9:01 PM EDT

A New Jersey federal judge granted drugmakers Celgene and Bristol-Myers Squibb an out from consolidated antitrust litigation accusing them of delaying generic competition to their blockbuster cancer treatments, saying the conduct...

To view the full article, register now.

Documents

Case Information

Case Title

IN RE REVLIMID & THALOMID PURCHASER ANTITRUST LITIGATION

Case Number

2:19-cv-07532

Court

New Jersey

Nature of Suit

Anti-Trust

Date Filed

March 01, 2019